Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189.

about

Late-Stage Microsomal Oxidation Reduces Drug-Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189.

Item

http://www.wikidata.org/entity/Q49874443

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Late-Stage Microsomal Oxidatio ...... rase 2A Inhibitor PF-06815189.

@en

Late-Stage Microsomal Oxidatio ...... rase 2A Inhibitor PF-06815189.

@nl

type

Item

label

Late-Stage Microsomal Oxidatio ...... rase 2A Inhibitor PF-06815189.

@en

Late-Stage Microsomal Oxidatio ...... rase 2A Inhibitor PF-06815189.

@nl

prefLabel

Late-Stage Microsomal Oxidatio ...... rase 2A Inhibitor PF-06815189.

@en

Late-Stage Microsomal Oxidatio ...... rase 2A Inhibitor PF-06815189.

@nl

P1476

Late-Stage Microsomal Oxidatio ...... rase 2A Inhibitor PF-06815189.

@en

P2093

Ann S Wright

http://www.w3.org/2001/XMLSchema#string

Antonia F Stepan

http://www.w3.org/2001/XMLSchema#string

Bethany L Kormos

http://www.w3.org/2001/XMLSchema#string

Cheng Chang

http://www.w3.org/2001/XMLSchema#string

Christopher J Helal

http://www.w3.org/2001/XMLSchema#string

David Karanian

http://www.w3.org/2001/XMLSchema#string

Edward X Yang

http://www.w3.org/2001/XMLSchema#string

Ethan L Fisher

http://www.w3.org/2001/XMLSchema#string

Gregory S Walker

http://www.w3.org/2001/XMLSchema#string

Maria S Brown

http://www.w3.org/2001/XMLSchema#string

P2860

X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity

The vascular endothelium and human diseases

Oxidative diversification of amino acids and peptides by small-molecule iron catalysis

Can the pharmaceutical industry reduce attrition rates?

Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.

Clinical and molecular genetics of the phosphodiesterases (PDEs).

The medicinal chemist's toolbox for late stage functionalization of drug-like molecules.

Discovery of an Orally Bioavailable, Brain-Penetrating, In Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

P304

68-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSMEDCHEMLETT.7B00343

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29456790

http://www.w3.org/2001/XMLSchema#string

P932

5807869

http://www.w3.org/2001/XMLSchema#string